Marker Therapeutics (NASDAQ:MRKR) Coverage Initiated by Analysts at Canaccord Genuity Group

On March 8th, 2025, Canaccord Genuity Group announced the initiation of coverage for Marker Therapeutics (NASDAQ:MRKR) in a research report directed at investors. The analysts assigned a buy rating to the company with a target price of $8.00 per share.

Additionally, Brookline Capital Management upgraded Marker Therapeutics to a "strong-buy" rating in their report dated February 10th, indicating growing confidence in the company’s potential.

Marker Therapeutics Stock Performance

As of the latest trading session, shares of Marker Therapeutics opened at $1.50. Over the past year, the stock has reached a low of $1.35 and a high of $5.99. The company’s 50-day simple moving average stands at $2.16, while the 200-day average is $2.97.

Recent Insider Transactions

In recent insider news, Director Steve Elms purchased 11,085 shares of Marker Therapeutics on December 23rd, acquiring shares at an average price of $3.20 each. This totaled $35,472 for the transaction, increasing his ownership to 325,370 shares valued at approximately $1,041,184. This acquisition represents a 3.53% increase in his holdings.

Moreover, major shareholder Enterprise Associates 16 New also made a significant purchase, acquiring 554,250 shares at the same average price of $3.20, amounting to a total investment of around $1,773,600. Post-transaction, they now own 1,625,678 shares valued at approximately $5,202,169.60, reflecting a 51.73% increase in their ownership. It is reported that insiders hold about 14.50% of the company's stock.

Institutional Investor Activity

Marker Therapeutics has seen notable activity from institutional investors. Several hedge funds have recently adjusted their stakes in the company. Millennium Management LLC invested $50,000 during the fourth quarter, while Invst LLC contributed around $56,000 in the third quarter. Additionally, Northern Trust Corp significantly increased its stake by 66.9% in the fourth quarter, holding 54,156 shares now valued at $168,000 after acquiring an extra 21,703 shares.

LPL Financial LLC also purchased a new stake in the fourth quarter worth about $248,000. Aisling Capital Management LP increased its stakes by 3.5% during the same quarter, now owning 325,370 shares valued at approximately $1,012,000. The overall institutional investors now account for 22.39% of Marker Therapeutics’ stock.

About Marker Therapeutics

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of innovative T cell-based immunotherapies for treating both hematological malignancies and solid tumors. The firm specializes in producing non-engineered tumor-specific T cells that target multiple tumor-associated antigens.

Marker, Therapeutics, Analysts